Search
  • FutureMeds

FutureMeds provides world-leading expertise in osteoporosis research

Almost all FDA approved osteoporosis medications have been investigated by FutureMeds’ Senior Medical Director, Professor Edward Czerwinski MD PhD.



Following the April 2020 acquisition of Krakow Medical Centre (KCM), KCM founder and world-renowned specialist and leader in the field of osteoporosis, prof. Edward Czerwinski MD PhD, was appointed Senior Medical Director. FutureMeds now stand as world leaders in osteoporosis clinical trials.


Edward is a Professor of the Jagiellonian University with 50 years of experience as a practising orthopaedic surgeon in addition to being an active university lecturer and scientist. As a former KCM director he and his team led 200 trials across a wide range of therapy areas such as phase II-IV cardiology, dermatology, rheumatology, neurology, nephrology and gastroenterology. He has been PI in 58 trials, in which 2,700 patients were enrolled.


In 46 osteoporosis trials in which over 1,650 patients have been participating, 12 osteoporosis drugs & compounds were investigated, including Alendronate, Ibandronate, Risedronate, Zoledronate, Strontium ranelate, Cathepsin, Lasofoxifene, Arzoxifene, Tibolone, Denosumab, Romosozumab and Abaloparatide. As a result of the team’s extensive work, almost all osteoporosis medications that have received FDA approval have been tested by Professor Edward Czerwinski’s clinical trial team.


24 conferences were organized by Professor Czerwinski in Poland, including the World Congress on Osteoporosis in 2018 and 8 Central European Congress on Osteoporosis. His current international memberships include scientific committees of IOF, EULAR, EFFORT and the boards of 10 scientific international magazines. Additionally, he is the founder and manager of Polish Portal on Osteoporosis and the author of over 530 publications.


Under his medical direction, FutureMeds’ Dedicated Site Network drives 3 times more patients per site than traditional sites. The high performing trial centers of FutureMeds’ Dedicated Site Network enhance patient experience and enable clients to access a wider and more diverse patient community.